Patents by Inventor Ann Logan
Ann Logan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793905Abstract: The invention relates to a surgical or wound dressing comprising a sheet of gellan gum and an antifibrotic agent. Methods of producing dressings comprising gellan gums and biologically active agents area also produced.Type: GrantFiled: August 14, 2019Date of Patent: October 24, 2023Assignee: THE UNIVERSITY OF BIRMINGHAMInventors: Liam Grover, Ann Logan, Felicity De Cogan, Gurpreet Chouhan
-
Publication number: 20220338788Abstract: Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and/or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.Type: ApplicationFiled: September 18, 2020Publication date: October 27, 2022Inventors: Neil EISENSTEIN, Carl BANBURY, Michael CLANCY, Pola Goldberg OPPENHEIMER, Richard BLANCH, Antonio BELLI, Ann LOGAN
-
Publication number: 20200038544Abstract: The invention relates to a surgical or wound dressing comprising a sheet of gellan gum and an antifibrotic agent. Methods of producing dressings comprising gellan gums and biologically active agents area also produced.Type: ApplicationFiled: August 14, 2019Publication date: February 6, 2020Inventors: Liam GROVER, Ann LOGAN, Felicity DE COGAN, Gurpreet CHOUHAN
-
Publication number: 20180272025Abstract: Described herein are surgical or wound dressings comprising a sheet of gellan gum and an antifibrotic agent. Methods for producing dressings comprising gellan gums and biologically active agents are also described.Type: ApplicationFiled: January 11, 2016Publication date: September 27, 2018Inventors: Liam GROVER, Ann LOGAN, Felicity DE COGAN, Gurpreet CHOUHAN
-
Publication number: 20180200340Abstract: The application discloses hydrogel wound treatment formulation containing collagen and decorin, and optionally fibrin. This is especially useful for the treatment of the eye. Wound dressings comprising the formulation are also provided, for example in the form of a gellan sheet.Type: ApplicationFiled: July 18, 2016Publication date: July 19, 2018Inventors: Liam GROVER, Ann LOGAN, Felicity Jane DE COGAN, Gurpreet CHOUHAN
-
Publication number: 20160339079Abstract: Described herein is a transmembrane delivery system comprising: a pharmaceutically active moiety; and a polypeptide of up to 20 amino acids in length comprising a continuous region of at least 2, more typically at least 4 basic amino acids. Typically the system comprises a polypeptide which has the formula: (B)n(A)m where B is a basic amino acid A is an acidic amino acid, m and n are integers, and n is at least 4, and m is less than n.Type: ApplicationFiled: January 28, 2015Publication date: November 24, 2016Inventors: Artemis STAMBOULIS, Ann LOGAN, Felicity Jane DE COGAN, Robert SCOTT, Anna Frances Acushla PEACOCK, Lisa Jayne HILL
-
Patent number: 7943755Abstract: The invention provides a gene silencing molecule, which is adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway. The gene silencing molecule is used to promote neuron survival and axon regeneration in the central nervous system (CNS). The invention also provides compositions and methods of using same to improve neural survival and promote axonal growth.Type: GrantFiled: October 22, 2004Date of Patent: May 17, 2011Assignee: Neuregenix LimitedInventors: Zubair Ahmed, Martin Berry, Ann Logan
-
Publication number: 20080253989Abstract: The invention provides a gene silencing molecule, which is adapted to down-regulate expression of a gene encoding a peptide involved with the Rho-A inhibitory pathway. The gene silencing molecule is used to promote neuron survival and axon regeneration in the central nervous system (CNS). The invention also provides compositions and methods of using same to improve neural survival and promote axonal growth.Type: ApplicationFiled: October 22, 2004Publication date: October 16, 2008Applicant: NEUREGENIX LIMITEDInventors: Zubair Ahmed, Martin Berry, Ann Logan
-
Publication number: 20080152689Abstract: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses compositions and devices that may further include a targeting agent, such as a polypeptide that is reactive with an FGF receptor (e.g., bFGF), or another ligand that binds to cell surface receptors on neuronal cells, or a support cell. The invention also discloses methods of promoting neuronal survival and regeneration via transfection of an axon as it grows through a device or composition of the present invention, or via transfection of a repair cell.Type: ApplicationFiled: December 6, 2007Publication date: June 26, 2008Applicants: TISSUE REPAIR COMPANY, KING'S COLLEGE, UNIVERSITY OF BIRMINGHAMInventors: Andrew Baird, Ana Maria Gonzalez, Martin Berry, Ann Logan
-
Publication number: 20040138155Abstract: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses compositions and devices that may further include a targeting agent, such as a polypeptide that is reactive with an FGF receptor (e.g., bFGF), or another ligand that binds to cell surface receptors on neuronal cells, or a support cell. The invention also discloses methods of promoting neuronal survival and regeneration via transfection of an axon as it grows through a device or composition of the present invention, or via transfection of a repair cell.Type: ApplicationFiled: January 17, 2003Publication date: July 15, 2004Applicants: Selective Genetics, Inc., University of Birmingham, King's CollegeInventors: Andrew Baird, Ana Maria Gonzalez, Ann Logan, Martin Berry
-
Publication number: 20030121064Abstract: The invention features a method for promoting neural growth in vivo in the mammalian central nervous system by delivering a composition comprising a combination of neurotrophins to promote neural growth. Active fragments, cognates, congeners, mimics, analogs, secreting cells and soluble molecules thereof, and DNA molecules, vectors and transformed cells capable of expressing them are similarly utilizable in the methods of the instant invention.Type: ApplicationFiled: November 13, 2002Publication date: June 26, 2003Inventors: Ann Logan, Martin Berry
-
Patent number: 6551618Abstract: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses compositions and devices that may further include a targeting agent, such as a polypeptide that is reactive with an FGF receptor (e.g., bFGF), or another ligand that binds to cell surface receptors on neuronal cells, or a support cell. The invention also discloses methods of promoting neuronal survival and regeneration via transfection of an axon as it grows through a device or composition of the present invention, or via transfection of a repair cell.Type: GrantFiled: October 23, 1998Date of Patent: April 22, 2003Assignees: University of Birmingham, King's College, Selective Genetics, Inc.Inventors: Andrew Baird, Ana Maria Gonzalez, Ann Logan, Martin Berry
-
Patent number: 5958411Abstract: The present invention relates to methods for preventing, suppressing or treating a CNS pathology characterized by a deleterious accumulation of extracellular matrix in a tissue by contacting the tissue with an agent that inhibits the extracellular matrix producing activity of TGF-.beta.. The methods can be used to prevent, suppress or treat scar formation in the CNS. Agents that are useful in the present methods include neutralizing anti-TGF-.beta. antibodies, Arg-Gly-Asp-containing peptides, decorin and its functional equivalents such as biglycan, and TGF-.beta. antagonists. The present invention further provides methods for preventing, suppressing or treating a CNS pathology characterized by the insufficient accumulation of extracellular matrix. Agents that enhance the production of extracellular matrix, such as TGF-.beta., can be used in such methods.Type: GrantFiled: March 24, 1995Date of Patent: September 28, 1999Assignee: The Whittier Institute for Diabetes and EndocrinologyInventors: Ann Logan, Andrew Baird